Altimmune announces Q3 earnings per share of 21 cents, below consensus estimate of 27 cents.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Should l Buy ALT?
Q3 Revenue Report: Altimmune reported Q3 revenue of $5,000, significantly below the consensus estimate of $560,000, while highlighting advancements in their pemvidutide MASH program.
Upcoming Milestones: The company anticipates two key milestones, including an End-of-Phase 2 meeting with the FDA and the release of 48-week data from the IMPACT trial, which will inform the design of their Phase 3 MASH trial.
RECLAIM Trial Progress: Altimmune has completed patient recruitment for the RECLAIM trial focused on pemvidutide for alcohol use disorder, indicating a strong unmet need in this area.
Leadership Additions: The company is enhancing its management team with new appointments, including Dr. Christophe Arbet-Engels as Chief Medical Officer, Linda Richardson as Chief Commercial Officer, and Robin Abrams as Chief Legal Officer, all of whom bring significant expertise.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.470
Low
12.00
Averages
13.00
High
14.00
Current: 5.470
Low
12.00
Averages
13.00
High
14.00
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune Closes Direct Offering of 17 Million Shares Raising $75 Million
- Funding Size: Altimmune successfully closed a registered direct offering of 17,045,454 shares, raising approximately $75 million, which will support the upcoming Phase 3 trial for pemvidutide.
- Trial Preparation: The proceeds will be allocated towards the initiation of the Phase 3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), aimed at validating the efficacy of pemvidutide and enhancing the company's market competitiveness in liver disease treatment.
- Strategic Flexibility: CEO Jerry Durso emphasized that this financing strengthens Altimmune's balance sheet and increases operational and strategic flexibility, ensuring the company can continue delivering meaningful impacts for patients and long-term value for shareholders.
- Market Response: The pre-funded warrants in the offering have an exercise price of $0.001 per share, are exercisable immediately, and have no expiration date, reflecting investor confidence in Altimmune's future developments, which may positively influence the company's stock price.
See More
Longevity Infrastructure Market Undergoes Structural Reset
- Market Size Surge: The global longevity infrastructure is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Growth: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are set to accelerate to $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell encapsulation technology and precision metabolic delivery.
- Technological Innovation Breakthrough: Avant Technologies' Cell-in-a-Box® technology addresses the critical issue of transplanted cells being destroyed by the immune system by creating a protective barrier around them, thus eliminating the need for immunosuppressive drugs and enhancing the safety and scalability of diabetes therapies.
- Massive Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SG Austria to develop a bioartificial pancreas aims to restore natural glucose control and meet the demands of this vast market.
See More
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
See More
Altimmune Announces $75 Million Stock Offering Amid Market Volatility
- Stock Offering Impact: Altimmune's announcement of a direct offering of 17,045,454 shares at approximately $4.40 each is expected to generate about $75 million in gross proceeds, yet this has led to a 17.15% drop in stock price, indicating market concerns over its funding strategy.
- Clear Use of Funds: The proceeds from this offering will be allocated to preparations for the upcoming Phase 3 trial for MASH (metabolic dysfunction-associated steatohepatitis) and general working capital, highlighting the company's commitment to advancing its drug development.
- Market Performance Analysis: Despite a 26.33% decline in share price over the past year, Altimmune's stock remains above its 20-day and 100-day simple moving averages, suggesting short-term strength; however, the RSI indicates overbought conditions, signaling potential correction risks ahead.
- Product Development Outlook: Altimmune is developing pemvidutide as a potential treatment for obesity and metabolic-associated steatohepatitis, and the success of this funding will significantly impact its future market performance and growth trajectory.
See More
Qorvo Shares Drop After Disappointing Earnings Guidance
- Disappointing Earnings: Qorvo reported third-quarter financial results with fourth-quarter revenue guidance projected between $775 million and $825 million, significantly below the market estimate of $904.59 million, indicating sales pressure on the company.
- Lowered Earnings Expectations: The company anticipates adjusted earnings per share in the range of $1.05 to $1.35 for the fourth quarter, compared to the market expectation of $1.37, reflecting potential declines in profitability.
- Significant Stock Reaction: In pre-market trading, Qorvo shares fell 10.5% to $74.11, as investor concerns over the financial outlook weakened market confidence.
- Market Trend Divergence: While Nasdaq 100 futures rose over 200 points, Qorvo's negative earnings report impacted its stock price, highlighting a divergence between individual stock performance and overall market trends.
See More
F5, Inc. Reports Strong Q1 Results and Raises FY26 Guidance
- Earnings Beat: F5, Inc. reported Q1 earnings of $4.45 per share, exceeding analyst expectations of $3.65 by 21.88%, indicating a significant improvement in profitability that is likely to positively impact stock prices.
- Revenue Growth: The quarterly revenue reached $822.47 million, surpassing the Street estimate of $758.08 million, demonstrating enhanced competitiveness in the market that may attract more investor interest.
- Optimistic Outlook: The company provided second-quarter sales guidance above estimates and raised its FY26 guidance, reflecting management's confidence in future growth, which could further drive stock price increases.
- Positive Stock Reaction: F5 shares jumped 10.9% to $299.99 in pre-market trading, indicating strong market response to its earnings report, which may draw in more investors and bolster market confidence.
See More
Altimmune Closes Direct Offering of 17 Million Shares Raising $75 Million
- Funding Size: Altimmune successfully closed a registered direct offering of 17,045,454 shares, raising approximately $75 million, which will support the upcoming Phase 3 trial for pemvidutide.
- Trial Preparation: The proceeds will be allocated towards the initiation of the Phase 3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), aimed at validating the efficacy of pemvidutide and enhancing the company's market competitiveness in liver disease treatment.
- Strategic Flexibility: CEO Jerry Durso emphasized that this financing strengthens Altimmune's balance sheet and increases operational and strategic flexibility, ensuring the company can continue delivering meaningful impacts for patients and long-term value for shareholders.
- Market Response: The pre-funded warrants in the offering have an exercise price of $0.001 per share, are exercisable immediately, and have no expiration date, reflecting investor confidence in Altimmune's future developments, which may positively influence the company's stock price.
See More
Longevity Infrastructure Market Undergoes Structural Reset
- Market Size Surge: The global longevity infrastructure is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Growth: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are set to accelerate to $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell encapsulation technology and precision metabolic delivery.
- Technological Innovation Breakthrough: Avant Technologies' Cell-in-a-Box® technology addresses the critical issue of transplanted cells being destroyed by the immune system by creating a protective barrier around them, thus eliminating the need for immunosuppressive drugs and enhancing the safety and scalability of diabetes therapies.
- Massive Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SG Austria to develop a bioartificial pancreas aims to restore natural glucose control and meet the demands of this vast market.
See More
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
See More
Altimmune Announces $75 Million Stock Offering Amid Market Volatility
- Stock Offering Impact: Altimmune's announcement of a direct offering of 17,045,454 shares at approximately $4.40 each is expected to generate about $75 million in gross proceeds, yet this has led to a 17.15% drop in stock price, indicating market concerns over its funding strategy.
- Clear Use of Funds: The proceeds from this offering will be allocated to preparations for the upcoming Phase 3 trial for MASH (metabolic dysfunction-associated steatohepatitis) and general working capital, highlighting the company's commitment to advancing its drug development.
- Market Performance Analysis: Despite a 26.33% decline in share price over the past year, Altimmune's stock remains above its 20-day and 100-day simple moving averages, suggesting short-term strength; however, the RSI indicates overbought conditions, signaling potential correction risks ahead.
- Product Development Outlook: Altimmune is developing pemvidutide as a potential treatment for obesity and metabolic-associated steatohepatitis, and the success of this funding will significantly impact its future market performance and growth trajectory.
See More
Qorvo Shares Drop After Disappointing Earnings Guidance
- Disappointing Earnings: Qorvo reported third-quarter financial results with fourth-quarter revenue guidance projected between $775 million and $825 million, significantly below the market estimate of $904.59 million, indicating sales pressure on the company.
- Lowered Earnings Expectations: The company anticipates adjusted earnings per share in the range of $1.05 to $1.35 for the fourth quarter, compared to the market expectation of $1.37, reflecting potential declines in profitability.
- Significant Stock Reaction: In pre-market trading, Qorvo shares fell 10.5% to $74.11, as investor concerns over the financial outlook weakened market confidence.
- Market Trend Divergence: While Nasdaq 100 futures rose over 200 points, Qorvo's negative earnings report impacted its stock price, highlighting a divergence between individual stock performance and overall market trends.
See More
F5, Inc. Reports Strong Q1 Results and Raises FY26 Guidance
- Earnings Beat: F5, Inc. reported Q1 earnings of $4.45 per share, exceeding analyst expectations of $3.65 by 21.88%, indicating a significant improvement in profitability that is likely to positively impact stock prices.
- Revenue Growth: The quarterly revenue reached $822.47 million, surpassing the Street estimate of $758.08 million, demonstrating enhanced competitiveness in the market that may attract more investor interest.
- Optimistic Outlook: The company provided second-quarter sales guidance above estimates and raised its FY26 guidance, reflecting management's confidence in future growth, which could further drive stock price increases.
- Positive Stock Reaction: F5 shares jumped 10.9% to $299.99 in pre-market trading, indicating strong market response to its earnings report, which may draw in more investors and bolster market confidence.
See More
